CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 25 enrolled
Drug / intervention
Fluocinonidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00819507
NCT00819507Phase 4Completed
CompareCT.gov

Effects of a Novel Formulation of Fluocinonide 0.1% Cream on Skin Barrier Function in Atopic Dermatitis

Oregon Health and Science University·interventional·Posted Jan 9, 2009·Updated Jul 11, 2017

In Brief

A Phase 4 clinical trial evaluating Fluocinonide for Atopic Dermatitis. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the effect of short-term therapy using "VANOS Cream," a super-potent topical steroid cream on skin barrier function in patients with atopic dermatitis. This cream is already approved for this indication, but the investigators will further examine its effects on the skin barrier. This cream is a novel formulation of fluocinonide designed to enhance compliance with a cream base, but have the skin barrier repair properties of an ointment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
CollaboratorsMedicis Pharmaceutical Corporation

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 9, 2009
Enrollment StartJan 1, 2009
Primary CompletionJan 1, 2010
Study CompletionJun 21, 2010
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 17.5 years ago

Interventions

Fluocinonidedrug

Fluocinonide 0.1% cream topical daily for two weeks